Inventor · disambiguated record
William Haney
Also filed as: HANEY WILLIAM · HANEY WILLIAM G
13 granted patents·40 pending applications·82 citations·filing 1976–2025
91Inventor score
Top patents by PatentIndex Score
53 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0296US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0396US11834506B2Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Dec 5, 2023·16 cites·18 claims
- 0496US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0594US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0691US11884732B2Proteins binding HER2, NKG2D and CD16DRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Jan 30, 2024·6 cites·15 claims
- 0787US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 0887US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0986US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1080US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1179US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1279US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 1376US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1476US2023391877A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1576US2023357409A1Proteins binding nkg2d, cd16 and nectin4DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1675US2023227562A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1775US2023303702A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1874US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 1974US2024228625A1Proteins binding her2, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2074US2024166753A1Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2172US2024018266A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2271US4042327AIon-pairing chromatographyWATERS ASSOCIATES INC·Filed 1976·Granted Aug 16, 1977·21 cites·17 claims
- 2371US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2466US2021292420A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2565US2021130474A1Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2663US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2763US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2859US2022119533A1Heterodimeric fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2959US2021261668A1Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3058US2021130496A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3156US2020277383A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3256US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3353US2020002436A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3452US2020216544A1Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3552US2024117054A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3651US2021206859A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3750US2020376034A1Antibody variable domains targeting cd33, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3850US2021363261A1Protein binding nkg2d, cd16 and a fibroblast activation proteinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3950US2022025037A1Antibody variable domains targeting dll3, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4046US2021214436A1Multi-specific binding proteins and improvements thereonDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4146US2021238290A1Proteins binding nkg2d, cd16 and p-cadherinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4245US2020165344A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4345US2020277384A1Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4444US2020157174A1Proteins binding nkg2d, cd16 and ror1 or ror2DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4544US2021221894A1Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tamsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4643US2020231700A1Proteins binding gd2, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4743US2020157226A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4843US2020231679A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4943US2021130471A1Proteins binding cd33, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5043US2020157227A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when William Haney files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →